Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
  • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
  • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
  • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
  • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/02—Acyclic radicals, not substituted by cyclic structures
  • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
  • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
  • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
  • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
  • C07H7/02—Acyclic radicals
  • C07H7/033—Uronic acids

Definitions

• This invention is directed to intermediates, and a processes for the chemical synthesis of AT-III binding heparin or heparinoid, pentasaccharides.
• Vascular thrombosis is a cardiovascular disease indicated by the partial or total occlusion of a blood vessel by a clot containing blood cells and fibrin. In arteries, it results predominantly from platelet activation and leads to heart attack, angina or stroke, whereas venous thrombosis results in inflammation and pulmonary emboli.
• the coagulation of blood is the result of a cascade of events employing various enzymes collectively known as activated blood- coagulation factors. Heparin, a powerful anticoagulant has been used since the late 1930's in the treatment of thrombosis. In its original implementation, tolerance problems were noted and so reduced dosage was suggested to reduce bleeding and improve efficacy.
• Unfractioned heparin is primarily used as an anticoagulant for both therapeutic and surgical indications, and is usually derived from either bovine lung or porcine mucosa. Amongst the modern uses of unfractioned heparin are the management of unstable angina, an adjunct to chemotherapy and anti-inflammatory treatment, and as a modulation agent for growth factors and treatment of haemodynamic disorders.
• LMWHs low molecular weight heparins
• LMWH deep vein thrombosis
• heparins by chemical synthesis. This method would also provide the opportunity to develop second generation heparins or heparinoids, that can be tailored to target particular biological events in the blood coagulation cascade.
• the present invention provides composition of matter of intermediates, and a process for the synthesis, of AT-III binding heparins and heparinoids. What this entails is a stepwise synthetic process employing monosaccharide building blocks.
• AT-III binding pentasaccharide is such, that under cursory analysis of the individual monomeric units constituting the pentasaccharide, we note that each is distinct from the others. Secondly, we can see that there is an alternating stereospecificity in regard to the glycosidic linkages (Fig. 1).
• a protection strategy is required such that (1 ) sulphation can be effected at the required sites, whilst leaving some hydroxyl groups unsulphated (note that due to the chemical lability of N- and O-sulphates, sulphation needs to be effected late in the synthesis), (2) a protection strategy is required that assists in effecting the appropriate glycosidic linkage and (3) a protection strategy is required that enables the correct (in terms of regio- and stereoisomerism) glycosidic linkages to be formed.
• ⁇ -Glycosidic linkages are typically generated by the use of what are known as non-participating protecting groups, whilst ⁇ -linkages are effected by participating protecting groups.
• N- and O-participating and non-participating protecting groups are known to the art (the art being considered carbohydrate chemistry). It is also well known to the art that the kind of protecting groups employed can effect the reactivity of the building block. The culmination of these requirements are demonstrated in the exemplary building block in Fig. 2 below, which displays the kind of characteristics required to effect the synthesis of heparin oligosaccharides.
• X is a leaving group suitable of reacting with another monomer or acceptor, to form an interglycosidic linkage;
• R 1 is a non-participating amino protecting group so as to effect an -linkage upon activation of X followed by coupling to an appropriate acceptor;
• R 2 and R 4 can be similarly protected to allow for eventual O-sulphation, whilst R 3 is required to be differentially protected so as to allow the formation of an acceptor hydroxyl group to couple this block to the next in the chain.
• the building blocks in Fig. 3 exemplify the kind of derivatised monosaccharides required to effect the synthesis of heparin AT-III binding pentasaccharides.
• the protecting groups represented by 'Rs' in Fig. 3 are sites that will eventually require O-sulphation, the protecting groups represented by 'RH' need to be orthogonal to 'R s ' and represents sites that will eventually become hydroxyl groups.
• the substituents 'X ⁇ and 'X 2 ' represent leaving groups that are activated to react with another suitable protected building block to form a glycosidic linkage, and, in the case of X-i, may also be derivatised as alkyl glycosides or substituted with a group suitable to allow conjugation to a support for drug delivery.
• the 'R ' groups are protecting groups orthogonal to both 'Rs' and 'RH', and represent sites through which chain elongation via glycosylation occurs. 'R' is representative of either a protected or latent carboxylate function.
• the 'RA' groups are non-participating amino protecting groups that enable ⁇ -linkages to be formed while the 'R B ' groups may be either a participating or non-participating amino protecting group.
• the pentasaccharide can be constructed in a variety of different ways; blocks B and A can be coupled; blocks E and D can be coupled, block C can be coupled to either, and the resulting dimer and trimer can finally be coupled to form the pentasaccharide.
• each block can be added sequentially and so on.
• the invention provides for a monosaccharide building block in the D-glucopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula I,
• X-i includes but is not limited to: hydroxy, alkoxy, aryloxy, benzyloxy, substituted benzyloxy; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a 'butyldiphenylsilyloxy or other such substituted silyjoxy protecting group; a lipoaminoacid or other such group suitable for conjugation to delivery systems or solid supports; and the stereochemistry may be alpha or beta; other suitable groups will be known to those skilled in the art, RA includes but is not limited to: an azido function, an amine; an ⁇ /H-Dde, ⁇ /H- DTPM, ⁇ /H-Fmoc, ⁇ /H-Boc, NH-Cbz, ⁇ /H-Troc, A/-phthalimido; or, other such suitable protected amino functions known to those skilled
• the invention provides for a monosaccharide building block in the L-idopyrano conformation, for the preparation of synthetic heparinoids, said building block of General Formula II,
• X 2 includes but is not limited to: a hydroxyl group; thioalkyl, thioaryl, halogen, trichloroacetimidoyl, phosphate and related phosphate ester type leaving groups, or other suitable leaving group; a 'butyldiphenylsilyloxy or other such substituted silyloxy protecting group; and the stereochemistry may be alpha or beta; other suitabie groups will be known to those skilled in the art,
• RE includes but is not limited to: methyl, C 2 -C 5 alkyl; substituted alkyl; or, benzyl and substituted benzyl groups; other suitable groups will be known to those skilled in the art.
• the invention provides for a monosaccharide building block in the L-idopyrano configuration, for the preparation of synthetic heparinoids, said building block of General Formula III,
• RH is defined as in General Formula I,
• RM includes but is not limited to a p-methoxyphenyl protecting group or other suitable oxidatively labile protecting group; a trityl group; or, other such suitable protecting groups as known to those skilled in the art.
• the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula IV,
• RB includes but is not limited to: an azido function, an amine; an ⁇ /H-Dde or A/H-DTPM group; or other suitably protected amino functions as known to those skilled in the art, R is defined as in General Formula I, and Rs is defined as in General Formula I.
• the invention provides for a monosaccharide building block in the D-glucuronate configuration for the preparation of synthetic heparinoids, said building block of General Formula V,
• RP includes but is not limited to: 4-methoxyphenyl; substituted benzyl groups; alkylacyl, arylacyl and alkylarylacyl, or substituted alkylacyl, arylacyl and alkylarylacyl protecting groups; carbonate protecting groups; or, other suitable protecting groups as known to those skilled in the art.
• RL is defined as in General Formula I
• R E is defined as in General Formula II.
• the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula VI,
• X 2 is as defined as in General Formula II
• RB is defined as in General Formula IV
• RH may be selected independently and are defined as in General Formula I
• the invention provides for a monosaccharide building block in the D-glucopyrano configuration for the preparation of synthetic heparinoids, said building block of General Formula VII,
• RL and Rs may also together combine to form a benzylidene or substituted benzylidene ring.
• the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula VIII,
• X- t is defined as in General Formula I
• RHI is defined as being selected from RH of General Formula I, with the addition that RHI and RA can combine together to form a cyclic carbamate
• RA is defined as in General Formula I
• RHI and RA can combine together to form a cyclic carbamate
• Rs is defined as in General Formula I
• RH is defined as in General Formula I
• RL is defined as in General Formula I
• RE is defined as in General Formula II.
• the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula IX,
• Xi is as defined as in General Formula I
• RA is defined as in General Formula XIII
• RH I is defined as in General Formula XIII
• Rs is defined as in General Formula I
• Ru is defined as in General Formula I
• RM is defined as in General Formula III.
• the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula X,
• Rsi is defined as being selected from Rs of General Formula I, with the addition that R S ⁇ and R B can combine together to form a cyclic carbamate.
• RB is defined as in General Formula IV, with the addition that R S1 and R B can combine together to form a cyclic carbamate.
• Rs is defined as in General Formula I,
• RE is defined as in General Formula II.
• the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XI,
• RB is defined as in General Formula IV, with the addition that R B and R H2 can combine to form a cyclic carbamate
• RH2 is defined as being selected from RH of General Formula I, with the addition that RB and RH2 can combine to form a cyclic carbamate
• RH is defined as in General Formula I
• Rs is defined as in General Formula I.
• the invention provides for a disaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XII,
• X 2 is as defined in General Formula II
• Rp are defined as in General Formula V
• RM is defined as in General Formula III
• R B and RH 2 are as defined in General Formula XI
• RH isdefined as in General Formula I
• Rs is defined as in General Formula I.
• the invention provides for a disaccharide building biock for the preparation of synthetic heparinoids, said building block of General Formula XIII,
• X 2 is defined as in General Formula II
• RB and Rsi are defined as in General Formula X
• R s is defined as in General Formula I
• RP is defined as in General Formula V
• A includes but is not limited to; H, Methoxy, Methyl; other suitable substituents will be known to those in the art.
• the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIV,
• R B and Rsi are defined as in General Formula X, R s is defined as in General Formula I,
• RB-I is defined as being selected from R B of General Formula IV, with the addition that RBI can combine together with RH 2 to form a cyclic carbamate
• R H2 is defined as being selected from R H of General Formula I, with the addition that RH 2 can combine together with R B - ⁇ to form a cyclic carbamate
• RH is defined as in General Formula I.
• the invention provides for a trisaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XV,
• RH is defined as in General Formula I,
• RE is defined as in General Formula il,
• RB and Rsi are defined as in General Formula X, and RL is defined as in General Formula I.
• the invention provides for a tetrasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVI,
• R A and R H ⁇ are defined as in General Formula VIII, Rs is defined as in General Formula I,
• RH is defined as in General Formula I,
• the invention provides for a tetrasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XVII,
• RH is defined as in General Formula I,
• RB and Rsi are defined as in General Formula X,
• RB-I and RH2 are defined as in General Formula XIV.
• the invention provides for a pentasaccharide building block for the preparation of synthetic heparinoids, said building block of General Formula XIII,
• RA and RHI are defined as in General Formula VIII,
• RH is defined as in General Formula I,
• RB and R S1 are defined as in General Formula X,
• RBI and RH 2 are defined as in General Formula XIV.
• the invention provides a method for the preparation of compounds of the eighth aspect, involving the step of reacting a compound of the second or third aspect with a compound of the first or seventh aspect to form a new glycosidic bond.
• the invention provides a method for the preparation of compounds of the eighth aspect, involving the step of selectively removing the protecting group RM from compounds of the ninth aspect and oxidizing the product of said deprotection.
• the invention provides a method for the preparation of compounds of the tenth aspect, involving the step of reacting a compound of the fifth aspect with a compound of the fourth or seventh aspect to form a new glycosidic bond.
• the invention provides a method for the preparation of compounds of the eleventh aspect, involving the step of reacting a compound of the fifth aspect with a compound of the sixth or seventh aspect to form a new glycosidic bond.
• the invention provides a method for preparation of compounds of the thirteenth aspect involving the reaction of a compound of the fourth or seventh aspect with a suitable donor molecule, to form a new glycosidic bond.
• the invention provides a method for the preparation of compounds of the fourteenth aspect involving the step of using any one or more of the compounds of the fourth, fifth, sixth, seventh, tenth, eleventh, twelfth or thirteenth aspect in a glycosidic bond forming-reaction.
• the invention provides a method for the preparation of compounds of the fifteenth aspect involving the step of using any one or more compounds of the first, second, third, fourth, seventh, eighth and ninth aspects in a glycosidic bond forming reaction.
• the invention provides a method for the preparation of compounds of the sixteenth aspect involving the step of using any one or more of the compounds of the first, second third, fourth, fifth, seventh, eighth, ninth, tenth, thirteenth or fifteenth aspect in a glycosidic bond forming reaction.
• the invention provides a method for the preparation of compounds of the seventeenth aspect involving the step of using any one or more of the compounds of the second, third, fourth, fifth, seventh, tenth, eleventh, twelth, thirteenth or fourteenth aspect in a glycosidic bond forming reaction.
• the invention provides a method for the preparation of compounds of the eighteenth aspect involving the step of using any one or more of the compounds of the 1,2,3,4,5,7, 8, 9, 10, 11, 12, 13, 14, or 15, 16 or
• DIPEA Diisopropylethylamine
• DMAP 4- ⁇ /,/V-dimethylaminopyridine
• DMTST Dimethyl (methylthio)sulfoniumtetrafluoromethansulfonate
• DTPM (1 ,3-dimethyl-2,4,6 (1 H, 3H, 5H)-trioxopyrimidin-5-ylidene) methyl
• NBS A-Bromosuccinimide
• NIS ⁇ /-lodosuccinimide
• Pent ⁇ -Pentenyl
• Ph 3 P Triphenylphosphine
• TBDMS terf-Butyldimethylsilyl
• TBDPS terf-Butyldiphenylsilyl
• TFA Trifluoroacetic acid
• TFAA Trifluoroacetic acid anhydride
• Tf Trifluoromethanesulfonyl
• TfN 3 Trifluoromethanesulfonyl azide, prepared from NaN 3 and Tf 2 0,
• TfOH Trifluoromethanesulfonic acid
• TMS Trimethylsilyl, Tos: p-Toluenesulfonyl, p-TosOH: p-Toluenesulfonic acid,
• Trit Triphenylmethyl.
• Standard Operating Procedure 2 Formation of p-Methoxybenzylidene acetals
• Standard Operating Procedure 3 Formation of isopropylidene acetals:
• Standard Operating Procedure 4 Dealkylidenation (Removal of isopropylidene, benzylidene and p-methoxybenzylidene)
• Standard Operating Procedure 5 Regioselective opening of the p-methoxy- benzyliden acetal to a 6-O-pMethoxybenzyl ether
• Standard Operating Procedure 6 Regioselective opening of a benzylidene ring to a 4-O-benzyl ether
• Standard Operating Procedure 7 Introduction of a benzyl or p-methoxybenzyl ether
• Standard Operating Procedure 8 lntrodution of a terf-butyldiphenylsilyl ether Standard Operating Procedure 9: Cleavage of a ferf-Butyl-diphenylsilyl ether Standard Operating Procedure 10:lntroduction of a ⁇ /-DTPM-group Standard Operating Procedure 11 :Cleavage of a N-DTPM-group Standard Operating Procedure 12: Introduction of an azide group via diazo transfer reaction
• Standard Operating Procedure 13 Hydrolysis of thioglycosides (NBS) Standard Operating Procedure 14: Hydrolysis of thioglycosides (NIS) Standard Operating Procedure 15:Chemoselective Oxidation to Uronic acids Standard Operating Procedure 16: Methyl ester formation on the Uronic acids Standard Operating Procedure 17: Regioselective 6-O-Benzoylation Standard Operating Procedure 18: Common procedure for O-Benzoylation Standard Operating Procedure 19:Common procedure for O-Acetylation Standard Operating Procedure 20: PDC-oxidation of alcohols to carboxylic acids
• Standard Operating Procedure 21 Chemoselective 1-O-Benzoyl cleavage
• Standard Operating Procedure 22 Deacylation under Zemplen conditions
• Standard Operating Procedure 25 Formation of Trichloroacetimidates
• Standard Operating Procedure 26 Regioselective introduction of a 6-0- pMethoxyphenyl group under Mitsunobu conditions
• Standard Operating Procedure 27 Cleavage of the p-Methoxyphenyl ether
• Operating Procedure 28 Cleavage of p-Methoxybenzyl ethers
• Standard Operating Procedure 29 Formation of a 2,3-cyclic carbamate
• Standard Operating Procedure 30 Cleavage of the N-phthaloyl group
• Standard Operating Procedure 31 Introduction of a thiocresyi ether at the reducing end
• Standard Operating Procedure 32 Glycosylation with thioglycosides a) NIS-promoted glycosylation b) DMTST promoted glycosylations: Standard Operating Procedure 33: Glycosylations with trichloroacetimidates
• Standard Operating Procedure 34 Glycosylations using 2,3-cyclocarbamoyl protected pThiocresyl glycosides as glycosyl donors
• Standard Operating Procedure 35 Introduction of an Alloc-group Standard Operating Procedure 36: Cleavage of an Alloc-group Standard Operating Procedure 37: Lewis acid mediated benzylation
• the starting material (47.5 mmol) was dissolved in acetonitrile (100 - 200 ml) and reacted with benzaldehyde dimethyl acetal (1.2 equiv.) and a catalytic amount of p-toluenesulphonic acid monohydrate (0.01-0.1 equiv).
• the reaction was stirred at 50°C under reduced pressure (350 mbar) until the TLC shows completion. Subsequently, the mixture was neutralized with triethylamine (pH « 9) and concentrated in vacuo. The remaining residue was dissolved in an organic solvent (e.g. dichloromethane or ethyl acetate) and extracted with H 2 O, saturated brine solution, dried over Na 2 S0 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 95 %.
• Standard Operating Procedure 5 Regioselective opening of the p- methoxybenzyliden acetal to a 6-O-pMethoxybenzyl ether
• a suspension of the starting sugar (10.2 mmol), molecular sieves 3A (6.5 g, freshly activated) and Na(CN)BH 3 (3.85 g, 61.2 mmol) in dry DMF (90 ml) was stirred for 1 hr at r.t. and cooled down to 0°C. Subsequently, a solution of TFA (11.2 mL, 122.4 mmol in 51 mL dry DMF) was added dropwise and stirring continued at 50 to 60°C until completion of the reaction.
• the reaction mixture was cooled to 20°C, diluted with ethyl acetate and extracted with a saturated aqueous NaHC0 3 solution and filtered through a celite pad. The combined organic layers were washed with saturated brine solution, dried over MgS0 4 and concentrated. Final purification was achieved either by crystallization or by silica gel chromatography. The typical yields for the product formation varied between 70 and 90 %.
• the starting material (40.2 mmol) was dissolved in dry N,N'- dimethylformamide (100 mL) at 0°C and . reacted with NaH (48.24 mmol, 1.2 eq .per OH to be benzylated). Then benzyl bromide (1.1 eq per OH to be benzylated) was added dropwise and stirring continued at 0°C until completion. The same conditions were applied for the introduction of an allyl ether (Allylbromide served as allylating reagent).
• the starting thioglycoside (33.4 mmol) was suspended in 240 ml Acetone and 18 ml of distilled water and stirred for 45 min at -20°C. After addition of NIS (56.8 mmol) and TMSOTf (2.84 mmol) stirring was continued until completion. The reaction was stopped by addition of NaS 2 ⁇ 3 /NaHC0 3 (20 % aqueous solution , 1/1), diluted with ethyl acetate and washed with water and saturated brine solution. The organic layer was dried over Na 2 S0 4 and concentrated in vacuo. Final purification was achieved either by crystallization (e.g. petroleum spirit/ ethylacetate) or by silica gel chromatography. The typical yields for the product formation varied between 79 and 92 %.
• the starting material (1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with PDC (11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid.
• the reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether.
• the combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgS0 4 , evaporated and dried under high vacuum.
• Standard Operating Procedure 26 Regioselective introduction of a 6-O- pMethoxyphenyl group under Mitsunobu conditions
• a solution of the starting sugar (13.52 mmol), 4-methoxyphenol (20.3 mmol) and triphenylphosphine (20.3 mmol) in 85 ml dry dichloromethane was stirred at 0°C for 45 min.
• DEAD-reagent (22.9 mmol) at 0°C
• the reaction mixture was further stirred at room temperature until completion, filtered through a celite pad, diluted with dichloromethane and extracted with 10 % aqueous NaHC0 3 /NaOH solution (1/1 ), 10 % aqueous citric acid solution and aqueous saturated brine solution.
• the starting material (1.18 mmol) was dissolved in 30 ml acetonitrile and 7.5 ml water and cooled to 0°C. Subsequently, CAN (3.83 mmol) was added and stirring continued at 0°C until completion.
• the reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHC0 3 and back extracted with ethyl acetate. The combined organic layers were extracted with saturated aqueous NaHC0 3 solution and saturated brine solution, dried over MgS0 and evaporated. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 73 and 89 %.
• Standard Operating Procedure 28 Cleavage of p-Methoxybenzyl ethers
• the starting material (0.60 mmol) was dissolved in 27 ml acetonitrile and 3.0 ml water and cooled to 0°C. Subsequently, CAN (4.5 equiv.) was added and stirring continued from 0°C to room temperature until completion.
• the reaction mixture was diluted with ethyl acetate and extracted with water. The aqueous layer was made alkaline by addition of solid NaHC0 3 and back extracted with ethyl acetate. The combined organic layers were extracted with saturated aqueous NaHC0 3 solution and saturated brine solution, dried over MgS0 4 and evaporated. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 73 and 85 %.
• N-phthaloylated starting material (45.9 mmol) was dissolved in n-butanol (200 ml) and treated with 1 ,2-diaminoethane (50 ml) at 100°C. After stirring at 100°C until completion, the reaction mixture was concentrated in vacuo, coevaporated with toluene three times and dried under high vacuum. Final purification was achieved by silica gel chromatography. The typical yield for the product formation varied between 78 and 92 %.
• a mixture of glycosyl acceptor (1 mmol), thioglycoside (1 mmol) and 1.0 g of freshly activated molecular sieves in 20 ml of a dry solvent (e.g. CH 3 CN, CH 2 d 2, Toluene, Ether) was stirred for 45 min at r.t and cooled down to the reaction temperature. Subsequently, A/-lodosuccinimide (1.7 mmol) was added and stirring continued for 20 min at the reaction temperature. After the addition of a Lewis acid as promotor (e.g. TfOH, 85-170 ⁇ mol), stirring was continued at the reaction temperature until completion.
• a Lewis acid as promotor e.g. TfOH, 85-170 ⁇ mol
• a dry solvent e.g. CH 3 CN, CH 2 CI 2 , Toluene, Ether
• reaction mixture was quenched with triethyl amine, filtered through a celite pad and extracted with aqueous NaHC ⁇ 3 -solution, water and saturated brine solution, dried over Na 2 S0 4 , concentrated in vacuo and purified by silica gel column chromatography.
• the typical yields for the product formation varied between 50 and 85 %.
• PhSCI (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was added dropwise to a mixture of AgOTf (0.2 mmol) in dry dichloromethane (2 ml) at -78°C containing freshly activated molecular sieves 3 A. After stirring for 15 mins at -78°C, a solution of the thioglycoside (0.1 mmol, 1 equiv.) and DTBMP (0.2 mmol, 2 equiv.) in dry dichloromethane (2 ml) was slowly added.
• the glycosyl acceptor (0.2 mmol, 2 equiv.) in dry dichloromethane (1 ml) was slowly added and stirring continued until completion.
• the reaction was quenched with saturated aqueous NaHC0 3 solution (1 ml), warmed to rt and diluted with dichloromethane.
• the organic layer was dried over MgS0 4 , filtered and evaporated. Final purification was achieved by silica gel chromatography. The typical yields for the product formation varied between 60 and 90 %.
• the starting material (3.49 mmol) was dissolved in dry DMSO (20 ml) and cooled to 0°C. To the stirred solution were added successively benzyl bromide (3.5 equiv./OH-group), barium oxide (1.5 equiv/OH-group), catalytic amounts of TBAI ( 0.05 eqiv./OH-group) and potassium hydroxide (3.5 equiv./ OH- group). Stirring was continued from 0°C to rt until completion. The reaction was quenched with methanol, and further stirred for 30 min. After dilution with ether, the organic layer was washed with water and brine solution, dried over MgS0 and concentrated in vacuo. Final purification was achieved by silica gel chromatography.
• the starting material (0.3mmol ester groups) was dissolved in 11.8 ml of a mixture of water and THF (3:7), cooled to 0°C and reacted with 1 M aqueous NaOH-solution (5.0 ml). Stirring was continued until completion and the reaction mixture titurated with 10 % aqueous HCI-solution to a pH of 9.5. After evaporation of the THF, the mixture was freeze dried and the remaining residue purified by silica gel chromatography to yield the product. The typical yields for the product formation varied between 85 and 95 %.
• V-Acetyl-2-deoxy- ⁇ / ⁇ -D-glucopyranoside (8.5 g, 38.4mmol) was suspended in 100 ml dry methanol. Subsequently, 12.0 g Amberlite IR 120 iron exchange resin (H r -form) was added and the reaction mixture refluxed for 70 hrs at 65°C. After cooling to 25 °C, the iron exchange resin was removed by filtration and several times extracted with methanol. The combined methanol layers were neutralized with triethyl amine and concentrated in vacuo. The crude residue was purified by crystallization to furnish the title compound in 70 % yield ( ⁇ / ⁇ -mixture).
• Methyl glycoside A-1-i (20.6 mmol) was suspended in 100 ml aqueous NaOH solution (1 M) and stirred under reflux at 120°C until completion. After cooling and neutralization with 10 % aqueous HCI, the mixture was concentrated in vacuo and crude A-1-ii suspended in 200 ml methanol and reacted with N- [(1 ,3-dimethyl-2,4,6 (1 H,3H,5H)-trioxopyrimidin-5-ylidene) methyl]- ⁇ /', ⁇ /"-dime- thylamine (23.6 mmol) at 50°C (pH ⁇ 9.0) until completion.
• crude A-1 -iii was reacted with 150 mL acetylation mixture (pyridine/Ac 2 0, 2/1, v/v) until completion, concentrated in vacuo, coevaporated with toluene and dried.
• the residue was suspended in ethyl acetate and extracted with water, 10 % aqueous HCI, saturated, aqueous NaHC0 3 solution and H 2 0, dried over Na 2 S0 4 and concentrated.
• the crude residue was dissolved in dry methanol and reacted with a catalytic amount of NaOMe. After completion, the reaction was neutralized with Amberlite IR 120 and filtered. The organic layer was evaporated and dried to furnish the title compound A-1 -iii in 70 % yield (over 4 steps).
• Example 3 Synthesis of Building Block B-1, conditions: a) SOP 7, (95%); b) 60% aqueous Acetic acid, 60°C (90%); c) Methanesulfonyl chloride, Pyridine, 0°C-RT (87 %); d) Cesium Acetate, Ac 2 0, 120°C (95%); e) SOP 22, (92%); f) 1. 90% TFA, 0°C; 2. Ac 2 0, Pyridine; 3. SOP 31 , (73%, 3 steps); g) SOP 22, (98%); h) SOP 3, (92%); i) SOP 18, (98%); j) 80% acetic acid, 100°C (98%); k) SOP 26, (89%); I) SOP 23, (98%).
• B-1 -iii Preparation of B-1 -iii:
• B-1-ii (15.60 mmol) was dissolved in 60 % aqueous acetic acid (50 ml) and stirred at 60 °C until completion. After neutralization with solid NaHC0 3 , the mixture was evaporated and co evaporated with toluene. Crude B-1 -iii was dissolved in CHCI 3 /H 2 0, the organic layer separated, dried over Na 2 S04 and evaporated. The remaining residue was purified by a short silica gel chromatography to yield B-1 -iii in 90 % (4.43 g).
• B-1-x (8.0 mmol) was dissolved in 80 % aqueous AcOH and heated at 100°C until completion. The mixture was cooled to rt, neutralized with solid NaHC ⁇ 3 and dissolved in ethyl acetate/water (1/1 ). After removal of the aqueous layer, the organic layer was dried over MgS0 4 and evaporated to dryness furnishing B-1-xi in 98 % yield.
• Example 4 Synthesis of L-ido configured glycosyl donor B-2; a) SOP 2; b) SOP 18; c) SOP 5; d) SOP 23.
• Example 5 Synthesis of Building Blocks C-1, C-1 a and C-1b, conditions: a) SOP 19; b) SOP 13, (78 %, 2 steps); c) SOP 8, (91 %); d) SOP 22; e) SOP 2, (85%, 2 steps for C-1-vi ); f) SOP 18; g) SOP 5, (75 %, 2 steps for C-1).
• Example 7 Synthesis of several carbamoylated Building Blocks C-3a to C-3d and C-4a to C-4d, containing a 6-0 benzoyl or 6-O-p-methoxybenzyl protection
• Example 8 Synthesis of several 6-OMp and cyclic 2,3-carbamoyl protected building blocks C-5a to C-5c
• Example 9 Synthesis of building blocks C-6-a, C-6-b and C-7, conditions; a) SOP 12, (83 %); b) SOP 7; c) SOP 5, (75 %, 2steps); d) SOP 14 ( 82 %); e) SOP 8 (91 %).
• Compound C-6-a Compound C-6-a:
• Example 11 Synthesis of building block D-1 ; a) SOP 1 , (95 %); b) SOP 7, (85 %); c) SOP 13, (92 %); d) SOP 8; e) SOP 4, (70 %, 2 steps); f) 1. SOP 15; 2. SOP 16, (75 %, 2 steps).
• Example 12 Synthesis of Building Block D-2, conditions: a) 1. SOP 22; 2. SOP 1 ; b) SOP 7; c) 1. SOP 4; 2. TritCI, Pyridine, (CICH 2 ) 2 ; 3. SOP 23; d) 1. Cr0 3 , H 2 S0 4 , Acetone, 0°C, 2. SOP 16; e) 1. Dimethyl dioxirane , Acetone; 2. EtSH, TFAA, CH 2 CI 2 , 3. SOP 35.
• Example 13 Synthesis of Building Block D-3, conditions: a) 1. SOP 4, Amberlite IR 120, H 2 0, 80°C; 2. SOP 18, (85 %, 2 steps) b) 1. SOP 21 ; 2. SOP 8, ( 70 %, 2 steps); c) SOP 22, (96 %); d) 1. SOP 15; 2. SOP 16, (80 %, 2 steps); e) SOP 23, (92 %); f) SOP 9, (95 %); g) SOP 25a, (91 %).
• step 1 Preparation of D-3-i, step 1 :
• the starting material (57 mmol) and Amberlite IR 120 iron exchange resin (H + - form, 20 g) were suspended in water (180 ml) and stirred at 80 °C until completion.
• the iron exchange resin was removed by filtration and extracted with water The combined aqueous layers were neutralized with triethyl amine and freeze dried.
• Example 14 Syntheses of a range of block D donor sugars D-4 to D-7 from a common intermediate, a 4-O-levulinoyl glucal.
• E-1-ii-a A mixture of methyl 2-azido-2-deoxy-thio- ⁇ -D-glucopyranoside (10g, 42.5mmol) and imidazole (4.9g, 72.25 mmol) in 20 mL DMF was treated with terf-butyldiphenylchlorosilane (11.6mL, 44.63mmol) for 2h. The reaction mixture was concentrated, extracted, was
• Example 17 Preparation L-iduronic acid containing disaccharides B-A-1 to B- A-10; a) SOP 32a, (80 %, for B-A-1 ); b) SOP 27, (88 %, for B-A-5); c) 1.SOP 20; 2. SOP 16, (84 % for B-A-7, 2 steps); d) SOP 24, (94 %, for B-A-9).
• Disaccharide B-A-7 Formation of disaccharide B-A-7(step c)
• Disaccharide B-A-5 (1.00 g, 1.15 mol) was dissolved in anhydrous DMF (7.0 ml) and reacted with pyridinium dichromate (4.33 g, 11.5 mmol) under stirring at room temperature until complete conversion into the uronic acid.
• the reaction mixture was subsequently poured into 50 ml water and the whole extracted with diethyl ether.
• the -combined ether layers were washed with 10 % aqueous citric acid solution, filtered through a short silica gel pad, dried over MgS0 4 , evaporated and dried under high vacuum.
• E-D-1 was formed according to SOP 33 with ether as solvent at -30°C and
• E-D-4 was formed according to SOP 33 with ether as solvent at -30°C and TBDMSOTf as promotor in 84 % yield ( ⁇ / ⁇ -mixture).
• E-D-7 Methyl (2-azido-6-0-benzoyl-3,4-di-0-benzyl-2-deoxy- ⁇ -D-glucopyranosyl)-(1 ⁇ 4)-2, 3-di-O-benzyl- ⁇ -D-glucopyranosyl trichloroacetimidyl) uronate
• R J Bz, R ⁇ ⁇ ⁇ N 3 .
• E-D-27 was formed according to SOP 33 with ether as solvent at -20°C and
• TBDMSOTf as promotor in 70 % yield ( ⁇ / ⁇ -mixture).
• E-D-C-15 was formed according to SOP 33 with dichloromethane as solvent at O . to 20°C and TBDMSOTf as promotor in 70 % yield ( ⁇ / ⁇ -mixture).
• Example 22 Synthesis of trisaccharide E-D-C-17 to E-D-C-32, conditions: a) SOP 33.
• Example 23 Formation of trisaccharidic Trichloroacetimidates E-D-C-33 to E- D-C-48, conditions: a) 1. SOP 9; 2. SOP 25, (82% over 2 steps for E-D-C-47
• Example 24 Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-D-C-60
• D-C-1 SCres
• D-C-2 SCres
• D-C-3 SCres
• D-C-4 SCres
• R R 33 Bz E-D-C-51 :
• R 1 MD.
• R 2 All.
• Example 24 Syntheses of trisaccharides E-D-C-9 to E-D-C-12 and E-D-C-49 to E-D-C-60, conditions: a) 1. SOP 33; 2. SOP 24; b) SOP 33. (for D-C-5: 70 %, 2 steps); b) SOP 33, ( 78 % for E-D-C-9 as an ⁇ / ⁇ mixture).
• D-C-5 was formed according to SOP 33 with ether as solvent at -20°C and TMSOTf as promotor, followed by SOP 24 in 70 % yield (over 2 steps as ⁇ / ⁇ - mixture).
• E-D-C-9 was formed according to SOP 33 with ether as solvent at -20°C and TBDMSOTf as promotor in 78 % yield ( ⁇ / ⁇ -mixture).
• Example 25 Synthesis of trisaccharides E-D-C-41. E-D-C-42 and E-D-C-61 to E-D-C-66
• Example 25 Synthesis of trisaccharides E-D-C-41 , E-D-C-42 and E-D-C-61 to
• E-D-C-66 conditions: a) 1 . SOP 39; 2. SOP 38; 3. SOP 16; b) 1 . SOP 14; 2. SOP 25a.
• Example 26 An alternative route to the trisaccharides E-D-C-61 and E-D-C- 63
• Example 26 An alternative route to the trisaccharides E-D-C-61 and E-D-C- 63, conditions: a) 1. SOP 39; 2. SOP 38; 3. SOP 16; 4. Pd(Ph 3 P) 4 , p- TolS0 2 Na, THF, MeOH; b) SOP 33.
• Example 27 Syntheses of blocks E-D-C-67 to E-D-C-70
• Example 27 Syntheses of trisaccharides E-D-C-67 to E-D-C-70, conditions: a) SOP 33; b) SOP 24; c) SOP 33; d) 1. SOP 36; 2. SOP 37.
• Example 28 Synthesis of trisaccharides E-D-C-70 and E-D-C-71
• Example 28 Synthesis of trisaccharides E-D-C-70 and E-D-C-71 , conditions: a) SOP 33, (55% for E-D-C-71 , ⁇ / ⁇ mixture).
• E-D-C-71 was formed according to SOP 33 with dichloromethane as solvent at 40°C and TBDMSOTf as promotor in 55 % yield (as ⁇ / ⁇ -mixture).
• Example 29 Syntheses of trisaccharides E-D-C-61. E-D-C-72 and E-D-C-73
• Example 29 Syntheses of trisaccharides E-D-C-72 to E-D-C-73 and E-D-C- 61 , conditions: a) SOP 33; b) SOP 24; c) SOP 33.
• Example 30 Syntheses of trisaccharides C-B-A-1 to C-B-A-4, conditions: a) SOP 33; b) SOP 32a; c) 1. SOP 27; 2. SOP 20; 3. SOP 16; 4. SOP 24.
• Example 32 Syntheses of D-C-B-trisaccharides D-C-B-1 to D-C-B-3, conditions: a) 1. SOP 33; 2. SOP 36; 3. SOP 37.
• Example 33 Syntheses of D-C-B trisaccharides D-C-B-4 to D-C-B-7.
• Example 34 Syntheses of tetrasaccharides D-C-B-A-1 to D-C-B-A-2
• Example 34 Syntheses of tetrasaccharides D-C-B-A-1 and D-C-B-A-2, conditions: a) SOP 32a; b)1. SOP 36; 2. SOP 37; 3. SOP 24.
• Example 35 Alternative synthesis of tetrasaccharide D-C-B-A-2, conditions: a) 1. SOP 34; 2. SOP 24.
• Example 36 Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8
• Example 36 Syntheses of tetrasaccharides D-C-B-A-3 to D-C-B-A-8, conditions: a) 1 SOP 32b; 2. SOP 24.
• Example 37 Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4
• Example 37 Syntheses of tetrasaccharides E-D-C-B-1 to E-D-C-B-4, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
• Example 38 Syntheses of blocks E-D-C-B-5 to E-D-C-B-8
• Example 38 Syntheses of tetrasaccharides E-D-C-B-5 to E-D-C-B-8, conditions: a) SOP 33; b) 1. SOP 36; 2. SOP 37.
• Example 39 Syntheses of E-D-C-B-A pentasaccharides P-1 and P-2, conditions: a) SOP 34.
• Example 40 Synthesis of E-D-C-B-A pentasaccharide P-3 to P-26, conditions: a) SOP 33 (75 % for P-19 as an ⁇ / ⁇ mixture).
• P-19 was formed according to SOP 33 with dichloromethane as solvent at
• Example 41 Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P-12, P-19, P-20 and P-27
• Example 41 Alternative syntheses of E-D-C-B-A pentasaccharides P-11, P- 12, P-19, P-20 and P-27, conditions: a) SOP 32a.
• Example 43 Svnthesis of pentasaccharide P-13 and P-30
• Example 43 Formation of pentasaccharides P-13 and P-30, conditions: a) SOP 32a.
• Example 45 Partial deprotection of pentasaccharide P-19, conditions: a) SOP 28, 84%; b) SOP 39, 86%.
• Example 46 Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection
• Example 46 Partial deprotection of pentasaccharide P-30, containing a DTPM-group as amino protection, conditions: a) 1. SOP 28; 2. SOP 39; b) 1. SOP 11 with MeNH 2 as primary amine and MeOH as solvent; 2. SOP 12.
• Example 47 Partial deprotection of pentasaccharide P-1. containing a cyclic carbamate as amino protection
• Example 47 Partial deprotection of pentasaccharide P-1 , containing a cyclic carbamate as amino protection, conditions: a) SOP 27; b) SOP 39; c) SOP 12.
• Example 48 Deprotection protocol for pentasaccharides P-37 of claim 4, conditions: a) 1. SOP 27 and 28; 2. SOP 39; 3. SOP 11 with MeNH 2 as primary amine and MeOH as solvent; 4. SOP 12.
• the transformation of P- 33 into P-40 has been performed according to literature: Petitou et al., Carbohydr. Res. 1987, 167, 67-75.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Crystallography & Structural Chemistry (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Cardiology (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Saccharide Compounds (AREA)
• Polysaccharides And Polysaccharide Derivatives (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Related Parent Applications (1)

Related Child Applications (4)

Publications (1)

Family

ID=34437858

Family Applications (1)

Country Status (10)

Cited By (11)

Families Citing this family (31)

Citations (13)

Family Cites Families (12)

• 2002
  • 2002-09-06 US US10/488,677 patent/US7541445B2/en not_active Expired - Fee Related
  • 2002-09-06 AU AU2002331426A patent/AU2002331426B2/en not_active Ceased
  • 2002-09-06 JP JP2003526933A patent/JP4688414B2/ja not_active Expired - Fee Related
  • 2002-09-06 CA CA2806561A patent/CA2806561C/en not_active Expired - Fee Related
  • 2002-09-06 DK DK02766941.5T patent/DK1440077T3/da active
  • 2002-09-06 PT PT2766941T patent/PT1440077E/pt unknown
  • 2002-09-06 CA CA2459562A patent/CA2459562C/en not_active Expired - Fee Related
  • 2002-09-06 EP EP12188642.8A patent/EP2557086A3/en not_active Withdrawn
  • 2002-09-06 CN CN028218558A patent/CN1558911B/zh not_active Expired - Fee Related
  • 2002-09-06 ES ES02766941T patent/ES2423888T3/es not_active Expired - Lifetime
  • 2002-09-06 WO PCT/AU2002/001228 patent/WO2003022860A1/en not_active Ceased
  • 2002-09-06 EP EP02766941.5A patent/EP1440077B1/en not_active Expired - Lifetime
  • 2002-09-06 CA CA2806604A patent/CA2806604C/en not_active Expired - Fee Related
  • 2002-09-06 CA CA2806723A patent/CA2806723C/en not_active Expired - Fee Related
• 2009
  • 2009-01-15 US US12/354,643 patent/US8114970B2/en not_active Expired - Fee Related
• 2011
  • 2011-12-14 US US13/326,060 patent/US8686131B2/en not_active Expired - Fee Related
  • 2011-12-14 US US13/326,147 patent/US8404833B2/en not_active Expired - Fee Related
• 2014
  • 2014-01-29 US US14/167,822 patent/US9243018B2/en not_active Expired - Fee Related

Patent Citations (14)

Non-Patent Citations (12)

Also Published As

Similar Documents

Legal Events